My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

402.37 -23.27 (-5.47%)

Delayed Quote Updated: 1:01 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

23 24 Next >

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 05, 2024

From Natera, Inc.

Via Business Wire

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

April 01, 2024

From Natera, Inc.

Via Business Wire

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

March 18, 2024

From Natera, Inc.

Via Business Wire

Recap: Natera Q4 Earnings ↗

February 28, 2024

Via Benzinga

Earnings Preview For Natera ↗

February 27, 2024

Via Benzinga

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

March 14, 2024

From Natera, Inc.

Via Business Wire

Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades' ↗

March 12, 2024

On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Natera, Inc.

Via Benzinga

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

March 12, 2024

From Natera, Inc.

Via Business Wire

A Glimpse Into The Expert Outlook On Natera Through 9 Analysts ↗

February 20, 2024

Via Benzinga

There are signs that NASDAQ:NTRA may be ready to breakout. ↗

February 16, 2024

NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out.

Via Chartmill

9 Health Care Stocks Whale Activity In Today's Session ↗

March 08, 2024

Via Benzinga

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

March 07, 2024

From Natera, Inc.

Via Business Wire

Agilent Technologies Stock Getting Closer To Key Technical Benchmark ↗

March 05, 2024

Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71.

Via Investor's Business Daily

Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday? ↗

February 29, 2024

Wall Street exhaled a sigh of relief as the Federal Reserve’s favored gauge of inflation cooled as anticipated in January, quelling fears that an unexpected rise in the Consumer Price Index (CPI) might...

Via Benzinga

Topics Economy

Natera to Participate in March Investor Conferences

February 29, 2024

From Natera, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 28, 2024

Via Benzinga

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

From Natera, Inc.

Via Business Wire

Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗

February 27, 2024

On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades.

Via Benzinga

Earnings Scheduled For February 28, 2024 ↗

February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.

Via Benzinga

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

February 27, 2024

From Natera, Inc.

Via Business Wire

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

February 26, 2024

From Natera, Inc.

Via Business Wire

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

February 20, 2024

From Natera, Inc.

Via Business Wire

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy ↗

February 06, 2024

NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending.

Via InvestorPlace

Topics Bankruptcy

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy ↗

February 05, 2024

Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.

Via Benzinga

Topics Bankruptcy

Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling ↗

February 05, 2024

The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

New Study Validates Signatera™ in Endometrial Cancer

February 05, 2024

From Natera, Inc.

Via Business Wire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

January 30, 2024

From Natera, Inc.

Via Business Wire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.